Catalog No.
PHG17601
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human CD47 (Gln19-Pro139).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Leukocyte surface antigen CD47,CD47,Antigenic surface determinant protein OA3,IAP,Integrin-associated protein,Protein MER6,MER6
Purification
Purified by antigen affinity column.
Accession
Q08722
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. PMID: 19144521
Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis. PMID: 31214201
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. PMID: 26512116
Monoclonal anti-CD47 interference in red cell and platelet testing. PMID: 30516833
Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade. PMID: 30762908
Chemotherapy induces enrichment of CD47(+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells. PMID: 29367423
Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas. PMID: 31383641
CD47-signal regulatory protein alpha signaling system and its application to cancer immunotherapy. PMID: 29873856
Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPalpha Interaction as a Potential Cancer Immunotherapy. PMID: 32640189
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. PMID: 28378740
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. PMID: 31852716
TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. PMID: 27856600
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. PMID: 30878596
Durable antitumor responses to CD47 blockade require adaptive immune stimulation. PMID: 27091975
Phagocytosis checkpoints as new targets for cancer immunotherapy. PMID: 31462760
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. PMID: 19632178
Blockade of CD47 or SIRPalpha: a new cancer immunotherapy. PMID: 32799682
Targeting the CD47-SIRPalpha signaling axis: current studies on B-cell lymphoma immunotherapy. PMID: 30226089
Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases. PMID: 32733941
CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. PMID: 29667847
Dysregulated integrin alphaVbeta3 and CD47 signaling promotes joint inflammation, cartilage breakdown, and progression of osteoarthritis. PMID: 31534047
Targeting CD47 in Sezary syndrome with SIRPalphaFc. PMID: 30962222
Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases. PMID: 32061866
CD47: a potential immunotherapy target for eliminating cancer cells. PMID: 26830085
CD47 deficiency protects cardiomyocytes against hypoxia/reoxygenation injury by rescuing autophagic clearance. PMID: 31059044
Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry. PMID: 31421198
SIRP/CD47 signaling in neurological disorders. PMID: 25795378
Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. PMID: 31879362
Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. PMID: 18657508
The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury. PMID: 30392076
CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway. PMID: 29321087
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. PMID: 21178137
[CD47 receptor as a primary target for cancer therapy]. PMID: 28537232
CD47 limits autophagy to promote acute kidney injury. PMID: 31480863
For research use only. Not for human or drug use.
